|
Download PDF
|
Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend
first-line biologic position despite competition
Introduction
Datamonitor forecasts that total sales for the seven major
rheumatoid arthritis markets will grow from $7 billion in 2007
to over $12 billion in 2017. The sustained uptake of anti-TNFs
combined with the launch of several new biologic products will
drive growth in the short-and mid-term. However, biosimilar
entry will cause a small contraction in market value at the end
of the forecast period.
Scope
-
In-depth analysis of the current and future rheumatoid
arthritis market across the US, 5EU and Japanese markets, and a
'rest of world' snapshot.
-
Rheumatoid arthritis sales forecasts for over 20 key brands to
2017, and total brand figure to benchmark indication-specific
sales
-
Provides detailed brand analysis, including discussion of all
anti-TNFs and impact of alternative biologic products like Actemra
-
Assess the strategies of several key developers in the
rheumatoid arthritis market
Highlights
Simponi (golimumab) exemplifies a brand adopting both follow-on
and dual formulation strategies, but positioning with Remicade
will be challenging. Careful brand management, sales and
marketing efforts and a well executed switching strategy will
see Simponi achieve blockbuster status in the seven major
markets.
The TNF-failure pool will increase considerably as patients
cycle through a maximum of 2-3 TNF therapies. Currently, Orencia
and Rituxan/MabThera compete in this sub-population, which will
become increasingly crowded. With its well-perceived safety
profile and Actemra's US approval delay, Orencia will cement its
first-line position in TNF-failures.
Although some novel biologic products, have amassed convincing
efficacy data against anti-TNFs, their use will be limited to
the anti-TNF failure patient population, at least in the
mid-term. To progress up the treatment algorithm, new agents
need to demonstrate superiority to anti-TNFs and show
cost-effectiveness.
Reasons to Purchase
-
Quantify the current size of rheumatoid arthritis sales in the
seven major markets and understand trends in the Rest of World
-
Assess the commercial opportunities for non-anti-TNF biologic
products including Orencia, Rituxan/MabThera, Actemra,
ocrelizumab and ofatumumab
-
Detailed case studies analysing Simponi's product positioning
and epidemiology-based assessment of biologic therapies by line
and type of therapy
View
Table Of Contents >
|
